AMC Entertainment has given back more than half of Monday's post-earnings surge in a single session, yet the Street spent Tuesday and Wednesday raising price targets — a tension that frames this week's note neatly.
The analyst activity is the cleanest signal. Four separate firms raised targets in the past two days, a notable cluster for a stock at $2.20. Wedbush lifted its Outperform target from $3.00 to $4.00. Benchmark raised its Buy target to $3.00 from $2.50. Both B. Riley and Macquarie moved their Neutral targets up to $2.50, from $2.25 and $2.00 respectively. The direction is uniform — every recent move is an upgrade in price target, even if the rating mix stays split. The mean target across the panel is $2.72, implying roughly 24% upside from the current $2.20. The bull case rests on 53% projected EBITDA growth in 2026, margin expansion toward 12% by 2027, and a strong theatrical slate. Bears counter with a still-negative EBITDA projection of -$7 million on $955 million in revenue, persistent attendance headwinds, and fixed-cost pressure from rent obligations that eats into any attendance recovery. The Citigroup Sell rating, last updated in May with a $1.20 target, remains the outlier on the downside.
Options positioning muddies the picture. The put/call ratio climbed to 0.213 Tuesday — more than 2.6 standard deviations above its 20-day average of 0.192, and near the top of its 52-week range. That's the same defensive tilt flagged in the note published the morning after earnings. It hasn't unwound. Despite a 12% weekly gain on paper, options traders are still buying downside protection at an unusual rate. That reads as hedging against a giveback of the post-earnings move, not fresh directional conviction. The next earnings date is August 4 — close enough that the put demand makes mechanical sense.
Short positioning has stabilised after the pre-earnings scramble. Short interest ended Tuesday at 10.0% of the free float — roughly unchanged from where the previous note left it, and down about 130 basis points on the week in a slow drift rather than active covering. The borrow market remains wide open: availability runs at 547%, meaning there are more than five shares available for every one already lent out. Cost to borrow has fallen sharply, dropping 58% on the week to just 0.56%. These are not the conditions of a squeeze — the lending pool has room, shorts face little cost pressure, and the short score has drifted down to 43.4 from 46 a fortnight ago. The post-earnings dynamic confirmed what the July 15 note suspected: shorts trimmed ahead of the event, the stock moved anyway, and the squeeze story remains structurally off the table while availability stays this loose.
CEO Adam Aron bought 250,000 shares at $1.38 in May — the only meaningful insider purchase in the 90-day window, worth $344,000. The timing looks constructive in hindsight given where the stock has since traded, though the significance score was modest. Discovery Capital Management remains the most notable institutional holder at 6.2% of shares, having added 9.1 million shares as of the May 5 filing. BlackRock added 3.5 million shares through June 30. Passive and index flows are present but the ownership profile remains thin — only 99 institutional holders on record, a low count for an NYSE-listed name.
The August 4 print is now the next catalyst, and the framing will be less about whether the theatrical recovery is intact and more about whether EBITDA is tracking toward the positive territory bulls are projecting for 2027 — or whether the $7 million loss guidance is the more honest number.
See the live data behind this article on ORTEX.
Open AMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
